Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir

被引：0
|
作者：
Danielle Perez-Bercoff
Perrine Triqueneaux
Christine Lambert
Aboubacar Alassane Oumar
Anne-Marie Ternes
Sounkalo Dao
Patrick Goubau
Jean-Claude Schmit
Jean Ruelle
机构：
[1] CRP-Santé,Laboratoire de Rétrovirologie
[2] AIDS Reference Laboratory,UCLouvain
[3] de Pharmacie et d'Odontostomatologie de Bamako,Faculté de Médecine
[4] International center of Excellence Research Mali (ICER-Mali),undefined
来源：
Retrovirology | / 7卷
关键词：
Human Immunodeficiency Virus Type; Raltegravir; Replicative Capacity; Elvitegravir; I175M Mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] HIV-2 Integrase Variation in Integrase Inhibitor-Naive Adults in Senegal, West Africa
    Gottlieb, Geoffrey S.
    Smith, Robert A.
    Badiane, Ndeye Mery Dia
    Ba, Selly
    Hawes, Stephen E.
    Toure, Macoumba
    Starling, Alison K.
    Traore, Fatou
    Sall, Fatima
    Cherne, Stephen L.
    Stern, Joshua
    Wong, Kim G.
    Lu, Paul
    Kim, Moon
    Raugi, Dana N.
    Lam, Airin
    Mullins, James I.
    Kiviat, Nancy B.
    Sow, Papa Salif
    PLOS ONE, 2011, 6 (07):
  • [32] Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations
    Thi Thu Nga Nguyen
    Rato, Sylvie
    Molina, Jean-Michel
    Clavel, Francois
    Delaugerre, Constance
    Mammano, Fabrizio
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (03) : 731 - 738
  • [33] Effect of raltegravir resistance mutants in HIV-1 integrase on viral fitness and drug susceptibility
    Hu, Z.
    Kuritzkes, D. R.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A90 - A90
  • [34] Natural resistance of HIV-2 to zidovudine
    Reid, P
    MacInnes, H
    Cong, M
    Heneine, W
    García-Lerma, JG
    ANTIVIRAL THERAPY, 2004, 9 (04) : U41 - U41
  • [35] Resistance mutations in HIV-1 integrase selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors
    Goethals, O.
    Clayton, R.
    Wagemans, E.
    Van Ginderen, M.
    Vos, A.
    Geluykens, P.
    Dockx, K.
    Smits, V.
    Meersseman, G.
    Jochmans, D.
    Hallenberger, S.
    Hertogs, K.
    ANTIVIRAL THERAPY, 2008, 13 (04) : A11 - A11
  • [36] Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal
    Charpentier, Charlotte
    Larrouy, Lucile
    Matheron, Sophie
    Damond, Florence
    Delelis, Olivier
    Mouscadet, Jean-Francois
    Campa, Pauline
    Chene, Genevieve
    Brun-Vezinet, Francoise
    Descamps, Diane
    ANTIVIRAL THERAPY, 2011, 16 (06) : 937 - 940
  • [37] The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series
    Peterson, Kevin
    Ruelle, Jean
    Vekemans, Marc
    Siegal, Frederick P.
    Deayton, Jane R.
    Colebunders, Robert
    ANTIVIRAL THERAPY, 2012, 17 (06) : 1097 - 1100
  • [38] Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants
    Smith, Robert A.
    Raugi, Dana N.
    Wu, Vincent H.
    Zavala, Christopher G.
    Song, Jennifer
    Diallo, Khardiata Mbaye
    Seydi, Moussa
    Gottlieb, Geoffrey S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [39] Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility
    Van Baelen, Kurt
    Van Eygen, Veerle
    Rondelez, Evelien
    Stuyver, Lieven J.
    AIDS, 2008, 22 (14) : 1877 - 1880
  • [40] In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions
    Le Hingrat, Quentin
    Collin, Gilles
    Damond, Florence
    Peytavin, Gilles
    Lebourgeois, Samuel
    Ghosn, Jade
    Bachelard, Antoine
    Ferre, Valentine Marie
    Matheron, Sophie
    Descamps, Diane
    Charpentier, Charlotte
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (02) : 409 - 412
12345